Skip to contentpdufa.bio

icovamenib COVALENT-212

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

icovamenib COVALENT-212 is a Biomea Fusion, Inc. program in type 2 diabetes on GLP-1-based therapy. Its next catalyst is a Readout in Q2 2027.

BMEA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Type 2 diabetes on GLP-1-based therapy. Sponsor: Biomea Fusion, Inc. (BMEA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q2 2027BMEA

Questions

When is icovamenib COVALENT-212's next FDA decision or readout?

The next tracked catalyst for icovamenib COVALENT-212 is a Readout in Q2 2027.

What happened at icovamenib COVALENT-212's most recent FDA decision?

No FDA decision for icovamenib COVALENT-212 is in our archive yet.

What is icovamenib COVALENT-212 used for?

In our records icovamenib COVALENT-212 is under review or in development for Type 2 diabetes on GLP-1-based therapy.

Who makes icovamenib COVALENT-212?

Biomea Fusion, Inc. (BMEA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.